The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 12 March 2026•Updated 12 March 2026•

1 min read

Intensity Therapeutics Files to Resume Enrollment in Breast Cancer Study After Positive Data

Key Facts

1Preliminary results showed 71.4% of patients receiving INT230-6 achieved a pathological complete response (pCR) compared to 33% in the standard of care arm.

3 months ago

Version History

Version 13 months ago

What changed: The story was updated to include the company's filing to resume patient enrollment in the INVINCIBLE-4 study after revealing the trial had been on a temporary pause.

Intensity Therapeutics (INTS) has filed to resume patient enrollment in its Phase 2 INVINCIBLE-4 study for triple-negative breast cancer, following a previous pause in the trial. This move follows promising preliminary data showing that 71.4% of patients treated with INT230-6 achieved a pathological complete response (pCR), significantly outperforming the 33% rate in the standard care group. The study also demonstrated a superior safety profile, with a 44% reduction in severe adverse events. Resuming enrollment marks a critical step for the company as it advances its clinical development path and seeks to disrupt current oncology treatment standards. Market sentiment remains bullish as the company moves to capitalize on these strong efficacy and safety signals while resolving the trial's temporary pause.